Q32 Bio Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QTTB research report →
Range $14 – $66
Price Chart
About the company
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation.
- CEO
- Jodie Pope Morrison
- IPO
- 2018
- Employees
- 22
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on QTTB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $472.06M
- P/E
- 5.68
- PEG
- 0.02
- P/S
- 8.78
- P/B
- 3.05
- EV/EBITDA
- 10.72
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- 39.94%
- Net Margin
- 62.87%
- ROE
- 76.88%
- ROIC
- 19.43%
Latest fiscal year · YoY change
- Revenue
- $53.74M+0.0%
- Gross Profit
- $53.74M+0.0%
- Op Income
- $16.90M
- Net Income
- $29.82M+162.5%
- EPS
- $2.42+147.3%
- OCF Growth
- +50.5%
- FCF Growth
- +50.5%
- 52W High
- $23.57
- 52W Low
- $1.62
- 50D MA
- $14.41
- 200D MA
- $7.28
- Beta
- -0.33
- RSI (14)
- 54
- Avg Volume
- 1.53M
No earnings-call transcripts are available for QTTB yet.
- Free Float
- 45.1%
- Shares Outstanding
- 29.76M
- Float Shares
- 13.43M
of shares held by institutions
51 13F filers
Buy/sell ratio 13.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 321.05K | ▲ 25.64K |
| Cwm, LLC | 39 | ▲ 39 |
Held by 37 ETFs
Biggest fund positions in QTTB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 12, 26 | TZIANABOS ARTHUR | other | 10,826 |
| Jun 12, 26 | Lundberg Sven Ante | other | 10,826 |
| Jun 12, 26 | LAPORTE KATHLEEN | other | 10,826 |
| Jun 12, 26 | Iwicki Mark T | other | 10,826 |
| Jun 12, 26 | Xu Diyong | other | 10,826 |
| Jun 12, 26 | Manke Isaac | other | 10,826 |
| Jun 12, 26 | GRAYZEL DAVID S. | other | 10,826 |
| Jun 12, 26 | Thistle Mary | other | 10,826 |
| Jul 16, 26 | Violette Shelia M. | other | 37,500 |
| Jul 16, 26 | Morrison Jodie Pope | other | 132,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our QTTB coverage
Recent articles, reports, and earnings notes.
No research on QTTB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate QTTB report →Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
zacks.com · Aug 17
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
prnewswire.com · Aug 5
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet
zacks.com · Jul 31
Playing The Biotech Breakout With Insiders
seekingalpha.com · Jul 23
Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice
zacks.com · Jul 20
Q32 Bio: Bempikibart's Progress Keeps Me Bullish
seekingalpha.com · Jul 17
Wall Street Analysts See an 80.12% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
zacks.com · Jul 15
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
prnewswire.com · Jul 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.